BOIRON SA (BOI.PA) Stock Fundamental Analysis
EPA:BOI - Euronext Paris - Matif - FR0000061129 - Common Stock - Currency: EUR
We assign a fundamental rating of 5 out of 10 to BOI. BOI was compared to 51 industry peers in the Pharmaceuticals industry. While BOI has a great health rating, there are worries on its profitability. BOI has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BOI had positive earnings in the past year.
BOI had a positive operating cash flow in the past year.
BOI had positive earnings in each of the past 5 years.
In the past 5 years BOI always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.97%, BOI is doing worse than 62.75% of the companies in the same industry.
Looking at the Return On Equity, with a value of 3.00%, BOI is doing worse than 62.75% of the companies in the same industry.
BOI has a worse Return On Invested Capital (2.54%) than 62.75% of its industry peers.
BOI had an Average Return On Invested Capital over the past 3 years of 5.61%. This is significantly below the industry average of 14.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.97% | ||
| ROE | 3% | ||
| ROIC | 2.54% |
ROA(3y)4.57%
ROA(5y)4.15%
ROE(3y)6.7%
ROE(5y)6.13%
ROIC(3y)5.61%
ROIC(5y)5.46%
1.3 Margins
Looking at the Profit Margin, with a value of 2.33%, BOI is in line with its industry, outperforming 41.18% of the companies in the same industry.
BOI's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 3.23%, BOI is doing worse than 60.78% of the companies in the same industry.
BOI's Operating Margin has declined in the last couple of years.
BOI has a better Gross Margin (73.58%) than 60.78% of its industry peers.
In the last couple of years the Gross Margin of BOI has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.23% | ||
| PM (TTM) | 2.33% | ||
| GM | 73.58% |
OM growth 3Y-32.06%
OM growth 5Y-23.58%
PM growth 3Y-28.17%
PM growth 5Y-20.44%
GM growth 3Y0.74%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BOI is destroying value.
The number of shares outstanding for BOI remains at a similar level compared to 1 year ago.
BOI has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BOI has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.24 indicates that BOI is not in any danger for bankruptcy at the moment.
With a Altman-Z score value of 3.24, BOI perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
BOI has a debt to FCF ratio of 0.63. This is a very positive value and a sign of high solvency as it would only need 0.63 years to pay back of all of its debts.
BOI has a Debt to FCF ratio of 0.63. This is amongst the best in the industry. BOI outperforms 94.12% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that BOI is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.03, BOI belongs to the best of the industry, outperforming 86.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.63 | ||
| Altman-Z | 3.24 |
ROIC/WACC0.32
WACC7.86%
2.3 Liquidity
A Current Ratio of 2.51 indicates that BOI has no problem at all paying its short term obligations.
BOI has a better Current ratio (2.51) than 82.35% of its industry peers.
BOI has a Quick Ratio of 1.61. This is a normal value and indicates that BOI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BOI (1.61) is better than 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.61 |
3. Growth
3.1 Past
The earnings per share for BOI have decreased strongly by -68.36% in the last year.
The earnings per share for BOI have been decreasing by -22.40% on average. This is quite bad
The Revenue has decreased by -1.15% in the past year.
BOI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.63% yearly.
EPS 1Y (TTM)-68.36%
EPS 3Y-26.29%
EPS 5Y-22.4%
EPS Q2Q%-60.69%
Revenue 1Y (TTM)-1.15%
Revenue growth 3Y2.32%
Revenue growth 5Y-2.63%
Sales Q2Q%2.31%
3.2 Future
Based on estimates for the next years, BOI will show a small growth in Earnings Per Share. The EPS will grow by 2.73% on average per year.
BOI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.54% yearly.
EPS Next Y5.53%
EPS Next 2Y2.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.95%
Revenue Next 2Y1.47%
Revenue Next 3Y8.32%
Revenue Next 5Y5.54%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 34.69, the valuation of BOI can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of BOI indicates a slightly more expensive valuation: BOI is more expensive than 60.78% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.34. BOI is valued slightly more expensive when compared to this.
A Price/Forward Earnings ratio of 9.75 indicates a reasonable valuation of BOI.
Based on the Price/Forward Earnings ratio, BOI is valued a bit cheaper than 72.55% of the companies in the same industry.
BOI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.69 | ||
| Fwd PE | 9.75 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BOI is valued cheaper than 90.20% of the companies in the same industry.
64.71% of the companies in the same industry are more expensive than BOI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.77 | ||
| EV/EBITDA | 5.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BOI does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)6.27
PEG (5Y)N/A
EPS Next 2Y2.73%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.18%, BOI is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.92, BOI pays a better dividend. On top of this BOI pays more dividend than 92.16% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, BOI pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.18% |
5.2 History
The dividend of BOI decreases each year by -1.41%.
Dividend Growth(5Y)-1.41%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
206.77% of the earnings are spent on dividend by BOI. This is not a sustainable payout ratio.
DP206.77%
EPS Next 2Y2.73%
EPS Next 3YN/A
EPA:BOI (6/19/2025, 5:24:00 PM)
22.55
-0.15 (-0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners5.63%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap395.75M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.18% |
Yearly Dividend1.35
Dividend Growth(5Y)-1.41%
DP206.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.69 | ||
| Fwd PE | 9.75 | ||
| P/S | 0.81 | ||
| P/FCF | 16.77 | ||
| P/OCF | 10.01 | ||
| P/B | 1.05 | ||
| P/tB | 1.53 | ||
| EV/EBITDA | 5.75 |
EPS(TTM)0.65
EY2.88%
EPS(NY)2.31
Fwd EY10.26%
FCF(TTM)1.34
FCFY5.96%
OCF(TTM)2.25
OCFY9.99%
SpS27.78
BVpS21.55
TBVpS14.77
PEG (NY)6.27
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.97% | ||
| ROE | 3% | ||
| ROCE | 3.39% | ||
| ROIC | 2.54% | ||
| ROICexc | 3.01% | ||
| ROICexgc | 4.32% | ||
| OM | 3.23% | ||
| PM (TTM) | 2.33% | ||
| GM | 73.58% | ||
| FCFM | 4.84% |
ROA(3y)4.57%
ROA(5y)4.15%
ROE(3y)6.7%
ROE(5y)6.13%
ROIC(3y)5.61%
ROIC(5y)5.46%
ROICexc(3y)8.01%
ROICexc(5y)8.34%
ROICexgc(3y)11.86%
ROICexgc(5y)12.41%
ROCE(3y)7.49%
ROCE(5y)7.29%
ROICexcg growth 3Y-33.41%
ROICexcg growth 5Y-24.37%
ROICexc growth 3Y-32.4%
ROICexc growth 5Y-24.82%
OM growth 3Y-32.06%
OM growth 5Y-23.58%
PM growth 3Y-28.17%
PM growth 5Y-20.44%
GM growth 3Y0.74%
GM growth 5Y-0.95%
F-Score7
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.63 | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 37.59% | ||
| Cap/Sales | 3.27% | ||
| Interest Coverage | 14.49 | ||
| Cash Conversion | 68.03% | ||
| Profit Quality | 208.21% | ||
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.61 | ||
| Altman-Z | 3.24 |
F-Score7
WACC7.86%
ROIC/WACC0.32
Cap/Depr(3y)71.98%
Cap/Depr(5y)71.7%
Cap/Sales(3y)3.47%
Cap/Sales(5y)3.78%
Profit Quality(3y)124.88%
Profit Quality(5y)120.26%
High Growth Momentum
Growth
EPS 1Y (TTM)-68.36%
EPS 3Y-26.29%
EPS 5Y-22.4%
EPS Q2Q%-60.69%
EPS Next Y5.53%
EPS Next 2Y2.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.15%
Revenue growth 3Y2.32%
Revenue growth 5Y-2.63%
Sales Q2Q%2.31%
Revenue Next Year2.95%
Revenue Next 2Y1.47%
Revenue Next 3Y8.32%
Revenue Next 5Y5.54%
EBIT growth 1Y-62.79%
EBIT growth 3Y-30.48%
EBIT growth 5Y-25.59%
EBIT Next Year86.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-14.06%
FCF growth 3Y22.31%
FCF growth 5Y12.1%
OCF growth 1Y-13.1%
OCF growth 3Y5.87%
OCF growth 5Y-4.91%